GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Total Liabilities
Switch to:

Biogen (MEX:BIIB) Total Liabilities

: MXN194,875 Mil (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Biogen's Total Liabilities for the quarter that ended in Mar. 2023 was MXN194,875 Mil.

Biogen's quarterly Total Liabilities declined from Sep. 2022 (MXN243,138.05 Mil) to Dec. 2022 (MXN217,686.49 Mil) and declined from Dec. 2022 (MXN217,686.49 Mil) to Mar. 2023 (MXN194,875.49 Mil).

Biogen's annual Total Liabilities declined from Dec. 2020 (MXN277,151.26 Mil) to Dec. 2021 (MXN264,991.65 Mil) and declined from Dec. 2021 (MXN264,991.65 Mil) to Dec. 2022 (MXN217,686.49 Mil).


Biogen Total Liabilities Historical Data

The historical data trend for Biogen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 240,672.09 262,063.47 277,151.26 264,991.65 217,686.49

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Liabilities Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 246,770.96 265,919.72 243,138.05 217,686.49 194,875.49

Biogen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biogen's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=63806.509+(128946.544+18408.123
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+6525.311+0)
=217,686

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=478706.734-261020.247
=217,686

Biogen's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=54343.572+(119139.842+16862.389
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+4529.682+0)
=194,875

Total Liabilities=Total Assets (Q: Mar. 2023 )-Total Equity (Q: Mar. 2023 )
=443386.16-248510.675
=194,875

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biogen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines